Upregulated OCT3 has the potential to improve the survival of colorectal cancer patients treated with (m)FOLFOX6 adjuvant chemotherapy
ConclusionsHigh OCT3 expression in CRC tissues may be a protective factor for CRC patients treated with (m)FOLFOX6.
Source: International Journal of Colorectal Disease - Category: Gastroenterology Source Type: research
More News: Academies | Cancer | Cancer & Oncology | Chemotherapy | China Health | Colorectal Cancer | Eloxatin | Gastroenterology | Organic | Study | Vitamin B9